Skip to main content

New England Journal of Medicine Archives

VUMC-led study finds Moderna COVID vaccine safe and effective for children

May. 12, 2022—  by Bill Snyder Moderna’s COVID-19 vaccine is safe and generates robust immune responses in children ages 6 to 11 years, a national clinical trial co-led by Vanderbilt University Medical Center vaccine expert C. Buddy Creech, MD, MPH, has found. The two-dose vaccine (given approximately one month apart) led to antibody responses in more than...

Read more


New study illustrates how much it would cost for cancer drugs covered under Medicare Part D

May. 10, 2022—A new study by Vanderbilt researchers highlights how some older Americans diagnosed with cancer can face unlimited out-of-pocket spending for prescription drugs under the current structure of the Medicare Part D benefit.

Read more


Study finds azithromycin use during RSV not useful in preventing recurrent wheezing, may cause harm

Feb. 28, 2022—Vanderbilt research on the impact of the antibiotic azithromycin during severe respiratory syncytial virus (RSV) bronchiolitis overwhelmingly support current national bronchiolitis guidelines, which recommend against antibiotics during acute bronchiolitis due to lack of effect on the acute illness.

Read more


International study supports dupilumab for treatment of moderate-to-severe asthma in children

Dec. 8, 2021—In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11 with moderate-to-severe asthma, offering a new option to these patients.

Read more


VUMC is pacesetter for national aspirin study

May. 20, 2021—According to an innovative large-scale clinical trial reported last week in the New England Journal of Medicine, a single daily baby aspirin (81 mg) or a single daily adult aspirin (325 mg) are equally safe and effective for prevention of adverse cardiovascular events for patients with established atherosclerotic cardiovascular disease.

Read more


Study finds recommended ICU sedatives equally safe, effective

Feb. 2, 2021—Sedative medications used in intensive care are associated with increased delirium, which is in turn connected with higher medical costs and greater risk of death and ICU-related dementia.

Read more


Treating appendicitis with antibiotics instead of surgery may be good option for some, but not all, patients

Oct. 5, 2020—Antibiotics instead of surgery may be a good choice for some, but not all, patients with appendicitis, according to results from a study reported today in the New England Journal of Medicine.

Read more


New data offer insights on COVID treatments for people with cancer

Jul. 22, 2020—Newly released data on treatment outcomes of people with cancer diagnosed with COVID-19 reveal a racial disparity in access to Remdesivir, an antiviral drug that has been shown to shorten hospital stays, and increased mortality associated with dexamethasone, a steroid that has had the opposite effect in the general patient population.

Read more


VUMC studies provide key positive results for COVID-19 vaccine in early-stage clinical trial

Jul. 14, 2020—An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial.

Read more


Article examines need for genotyping after stenting

Oct. 24, 2019—Genotyping can improve outcomes in patients who require anti-platelet therapy following stent placement to open narrowed or blocked coronary arteries and prevent a heart attack.

Read more


Vanderbilt health policy expert explains TennCare block grant proposal

Oct. 9, 2019—Tennessee has made an “opening bid” in its negotiations with the federal government about a block grant that could significantly change how TennCare functions for more than 1 million children and low-income individuals, and making sense of the complex proposal can be tricky.

Read more


Study identifies targeted therapy’s cardiac risks

Sep. 25, 2019—After a recent study showed that chronic lymphocytic leukemia patients who received ibrutinib as a frontline treatment had a 7% death rate, a new study offers a clearer picture on the reasons for the deaths.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more